Joint Working EXECUTIVE SUMMARY

Published on www.astrazeneca.co.uk

Joint Working between AstraZeneca UK Ltd and South Stoke West PCN

Revision to Executive Summary of Inputs (due to project extension)

Date of Preparation Feb 2025

Project title	INTERACT Project - INTEgRAted care Clinics To Improve PCN COPD Care
Aims and Objectives	Aim: Optimise the management of COPD in primary care and improve patient outcomes. Objectives: The main objective is to improve quality of life and outcomes for South Stoke West PCN patients. Through optimising COPD care, we aim to; prevent disease progression, reduce healthcare utilization through optimised care, reduce exacerbations, reduce hospitalisation, reduce requests for urgent GP attendance, reduce use of OCS (oral corticosteroids) where clinically appropriate, reduce SABA (Short Acting Beta Agonist) over-reliance where clinically appropriate, and ensure patients have a COPD care plan. It is intended that patient understanding of the disease, personalised COPD management and treatment options will be improved to increase patient adherence to the treatment and improve patient outcomes.
Anticipated benefits	Patient: Access to a proactive COPD review. Treated according to NICE COPD quality standards, with an objective to improve patient outcomes and improve quality of life. Understand better COPD disease, value of their personalised COPD management and treatment options. NHS: The project is expected to improve capacity for the South Stoke West PCN to deliver high quality COPD care and deliver spirometry for accurate diagnosis. Working alongside a local respiratory consultant will give an opportunity for upskilling of PCN staff. Improved COPD care will lead to a reduction in healthcare resource utilisation. Facilitation of appropriate use of medicines aligned to local and national guidance. To provide education to patients to improve patient outcomes and increase patient adherence to the treatment by improving patient understanding of the disease, value of personalised COPD management and treatment options. AstraZeneca: Better understanding of unmet patient and healthcare needs. An opportunity to provide evidence of partnership working with the NHS. Due to clinical reviews and improved understanding of COPD management prescription of licensed treatments for COPD might increase which may include AstraZeneca products.

Timeline	The project was initially planned to run from November 2023 until July 2024 and both parties have contributed resources for this initiative. However, due to some delays and continued demand to deliver the project, an extension was made to this joint working until December 2025.
References	[References]